Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03927040 · ClinicalTrials.gov registry record · NA
Transcranial Electromagnetic Treatment Against Alzheimer's Disease
A NA study, sponsored by NeuroEM Therapeutics.
- Completed
- Registry status
- NA
- Development phase
- 7
- Enrollment target
NCT03927040 is a NA study that has completed, run by NeuroEM Therapeutics. The registered enrollment target is 7 participants.
The verdict
NCT03927040, a NA study, has completed, sponsored by NeuroEM Therapeutics.
- COMPLETED
- Registry status
- NA
- Development phase
- 7 participants
- Enrollment target
Study Summary
This is an extension of EM 1000-1 wherein subjects who participated in the original study have been given the opportunity to participate in a 4-month extension of TEMT. Seven of the eight subjects in the original EM 1000-1 agreed to participate in this study extension. The time between completion of the initial study's 2-month treatment period and the beginning of this extension study's 4-month treatment period will range from 4 months to 13 months (due to staggered start of treatment in the initial study). This extension study's primary objective is to determine the effects of a follow-up treatment period of 4-months on performance of Alzheimer's Disease (AD) subjects in the same comprehensive array of cognitive tasks they performed in the initial 2-month treatment study. Baseline cognitive performance will be compared to performance at both 2-months into treatment and at the end of the 4-month treatment period. Secondary objectives include analysis of blood and CSF for AD markers and evaluation of safety throughout the treatment period.
Interventions
- DEVICE MemorEM 1000
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2019-04-15 |
| Est. Completion | 2020-10-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03927040
The ClinicalTrials.gov registry entry for NCT03927040 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NeuroEM Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MemorEM 1000 is the first listed.
NCT03927040 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03927040 about?
NCT03927040 is a clinical study titled "Transcranial Electromagnetic Treatment Against Alzheimer's Disease". This is an extension of EM 1000-1 wherein subjects who participated in the original study have been given the opportunity to participate in a 4-month extension of TEMT. Seven of the eight subjects in the original EM 1000-1 agreed to participate in this study extension. The time between completion of...
What is the current status of trial NCT03927040?
This trial is currently completed. It is a NA study. The enrollment target is 7 participants. The study started on 2019-04-15. Estimated completion is 2020-10-30.
What interventions are being tested in trial NCT03927040?
The interventions under investigation include: MemorEM 1000 (DEVICE).
Who is sponsoring clinical trial NCT03927040?
This trial is sponsored by NeuroEM Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.